Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2010, 3(5), 1491-1506; doi:10.3390/ph3051491

Critical Overview on the Benefits and Harms of Aspirin

 and *
Received: 15 March 2010; in revised form: 30 April 2010 / Accepted: 7 May 2010 / Published: 14 May 2010
(This article belongs to the collection Non-Steroidal Anti-Inflammatory Drugs)
View Full-Text   |   Download PDF [79 KB, uploaded 13 May 2010]   |   Browse Figure
Abstract: Aspirin is widely used internationally for a variety of indications, with the most prominent one being that of cardiovascular disease. However, aspirin has also been proposed as a treatment option in a diverse range of conditions such as diabetes mellitus, cancer prevention, and obstetrics. In our overview, we critically appraise the current evidence from recent systematic reviews and meta-analyses covering the benefits of aspirin across these conditions. We also look at evidence that some patients may not derive benefit due to the concept of aspirin resistance. Aspirin is also associated with the potential for significant harm, principally from haemorrhagic adverse events. We critically appraise the threat of haemorrhagic complications, and weigh up these risks against that of any potential benefit.
Keywords: aspirin; efficacy; adverse events aspirin; efficacy; adverse events
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |

MDPI and ACS Style

Kwok, C.S.; Loke, Y.K. Critical Overview on the Benefits and Harms of Aspirin. Pharmaceuticals 2010, 3, 1491-1506.

AMA Style

Kwok CS, Loke YK. Critical Overview on the Benefits and Harms of Aspirin. Pharmaceuticals. 2010; 3(5):1491-1506.

Chicago/Turabian Style

Kwok, Chun Shing; Loke, Yoon K. 2010. "Critical Overview on the Benefits and Harms of Aspirin." Pharmaceuticals 3, no. 5: 1491-1506.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert